These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26056104)

  • 1. Cost of nurse-managed latent tuberculous infection treatment among hard-to-reach immigrants in Israel.
    Bishara H; Ore L; Vinitsky O; Bshara H; Armaly N; Weiler-Ravell D
    Int J Tuberc Lung Dis; 2015 Jul; 19(7):799-804. PubMed ID: 26056104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Accessibility and compliance of Ethiopian immigrants to latent tuberculosis infection treatment].
    Bishara H; Ore L; Bshara H; Vinitsky O; Armaly N; Weiler-Ravell D
    Harefuah; 2014 Jan; 153(1):8-11, 66. PubMed ID: 24605398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of pediatric latent tuberculosis infection in a community health center clinic.
    Young J; Edick T; Klee D; O'Connor ME
    Pediatr Infect Dis J; 2012 Sep; 31(9):e147-51. PubMed ID: 22531235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent Tuberculosis Treatment among Hard-to-Reach Ethiopian Immigrants: Nurse-Managed Directly Observed versus Self-Administered Isoniazid Therapy.
    Bishara H; Green M; Saffouri A; Weiler-Ravell D
    Trop Med Infect Dis; 2023 Feb; 8(2):. PubMed ID: 36828539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
    BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study.
    Rubinowicz A; Bartlett G; MacGibbon B; Greenaway C; Ronald L; Munoz M; Menzies D
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1449-54. PubMed ID: 25517810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of latent tuberculosis infection screening and treatment among newly arriving immigrants in the Netherlands: A mixed methods pilot evaluation.
    Spruijt I; Erkens C; Suurmond J; Huisman E; Koenders M; Kouw P; Toumanian S; Cobelens F; van den Hof S
    PLoS One; 2019; 14(7):e0219252. PubMed ID: 31260502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.
    Dobler CC; Marks GB
    PLoS One; 2012; 7(11):e48900. PubMed ID: 23139824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of latent tuberculous infection and treatment completion for refugees in Philadelphia, PA, 2010-2012.
    Subedi P; Drezner KA; Dogbey MC; Newbern EC; Yun K; Scott KC; Garland JM; Altshuler MJ; Johnson CC
    Int J Tuberc Lung Dis; 2015 May; 19(5):565-9. PubMed ID: 25868025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rate of latent tuberculosis treatment completion in immigrants seeking asylum in Sweden.
    Olsson O; Winqvist N; Olsson M; Olsson P; Björkman P
    Infect Dis (Lond); 2018 Sep; 50(9):678-686. PubMed ID: 29620426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.
    Li J; Munsiff SS; Tarantino T; Dorsinville M
    Int J Infect Dis; 2010 Apr; 14(4):e292-7. PubMed ID: 19656705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB
    Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island.
    Kwara A; Herold JS; Machan JT; Carter EJ
    Chest; 2008 Apr; 133(4):862-8. PubMed ID: 18071014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children.
    Cruz AT; Starke JR
    Int J Tuberc Lung Dis; 2014 Sep; 18(9):1057-61. PubMed ID: 25189552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain.
    Anibarro L; Casas S; Paz-Esquete J; Gonzalez L; Pena A; Guerra MR; Sande D; Calviño L; Santin M;
    Int J Tuberc Lung Dis; 2010 Jun; 14(6):701-7. PubMed ID: 20487607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil.
    Machado A; Finkmoore B; Emodi K; Takenami I; Barbosa T; Tavares M; Reis MG; Arruda S; Riley LW
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):719-25. PubMed ID: 19460247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.
    Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L
    Value Health; 2013; 16(1):66-75. PubMed ID: 23337217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.